Mouse chronic social stress increases blood and brain kynurenine pathway activity and fear behaviour: Both effects are reversed by inhibition of indoleamine 2,3-dioxygenase

Brain, Behavior, and Immunity

Volumn 54, Issue , 2016, Pages 59-72

  Fuertig, René ^a   Azzinnari, Damiano ^b,c   Bergamini, Giorgio ^b,c   Cathomas, Flurin ^b   Sigrist, Hannes ^b   Seifritz, Erich ^b,c   Vavassori, Stefano ^d   Luippold, Andreas ^a   Hengerer, Bastian ^a   Ceci, Angelo ^a   Pryce, Christopher R ^b,c  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Anxiety; Depression; Fear conditioning; IDO1; Inflammation; Kynurenine pathway; Monoamines; Psychosocial stress

Indexed keywords

3 HYDROXYKYNURENINE; ESCITALOPRAM; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; TUMOR NECROSIS FACTOR ALPHA; 3-HYDROXYKYNURENINE; ANTIDEPRESSANT AGENT; CITALOPRAM; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; TRYPTOPHAN; TUMOR NECROSIS FACTOR;

AMINO ACID BLOOD LEVEL; AMINO ACID BRAIN LEVEL; AMYGDALA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC SOCIAL DEFEAT; CONDITIONING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEAR; GENE EXPRESSION; HIPPOCAMPUS; LEARNING; MALE; MEMORY; MENTAL STRESS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN; C57BL MOUSE; DRUG EFFECTS; DRUG THERAPY; ENZYMOLOGY; METABOLISM; MOTOR ACTIVITY; PSYCHOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; BRAIN; CITALOPRAM; FEAR; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENIC ACID; KYNURENINE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; STRESS, PSYCHOLOGICAL; TRYPTOPHAN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84960910975     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.12.020     Document Type: Article

References (85)

1. Agudelo L.Z., Femenia T., Orhan F., Porsmyr-Palmertz M., Goiny M., Martinez-Redondo V., Correla J.C., Izadi M., Bhat M., Schuppe-Koistinen I., Pettersson A.T., Ferreira D.M.S., Krook A., Barres R., Zierath J.R., Erhardt S., Lindskog M., Ruas J.L. Skeletal muscle PGC-1A1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 2014, 159:33-45.
2. Azzinnari D., Sigrist H., Staehli S., Palme R., Hildebrandt T., Leparc G., Hengerer B., Seifritz E., Pryce C.R. Mouse social stress induces increased fear conditioning, helplessness and fatigue to physical challenge together with markers of altered immune and dopamine function. Neuropharmacology 2014, 85:328-341.
3. Bay-Richter C., Linderholm K.R., Lim C.K., Samuelsson M., Träskman-Bendz L., Guillemin G.J., Erhardt S., Brundin L. A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality. Brain Behav. Immun. 2015, 43:110-117.
4. Biagioli M., Pinto M., Cesselli D., Zaninello M., Lazarevic D., Roncaglia P., Simone R., Viacouli C., Plessy C., Bertin N., Beltrami A., Kobayashi K., Gallo V., Santoro C., Ferrer I., Rivella S., Beltrami C.A., Carninci P., Raviola E., Gustincich S. Unexpected expression of a- and b-globin in mesencephalic dopaminergic neurons and glial cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:15454-15459.
5. Bierhaus A., Wolf J., Andrassy M., Rohleder N., Humpert P.M., Petrov D., Ferstl R., von Eynatten M., Wendt T., Rudofsky G., Joswig M., Morcos M., Schwaninger M., McEwen B., Kirschbaum C., Nawroth P.P. A mechanism converting psychosocial stress into mononuclear cell activation. PNAS 2003, 100:1920-1925.
6. Blanchard D.C., Griebel G., Blanchard R.J. Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci. Biobehav. Rev. 2001, 25:205-218.
7. Brocco M., Dekeyne A., Veiga S., Girardon S., Millan M.J. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake: a pharmacological characterization of diverse classes of antidepressant agents. Pharm. Biochem. Behav. 2002, 71:667-680.
8. Bruce T.O. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr. Psychiatry Reports 2008, 10:258-264.
9. Cathomas F., Fuertig R., Sigrist H., Newman G., Hoop V., Bizzozzero M., Mueller A., Ceci A., Hengerer B., Seifritz E., Fontana A., Pryce C.R. CD40-induced inflammation in mice leads to sustained emotional and cognitive dysfunctions coincident with altered tryptophan metabolsim: a model for depression-autoimmune disease comorbidity. Brain Behav. Immun. 2015, 50:125-140.
10. Chiarugi A., Meli E., Moroni F. Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J. Neurochem. 2001, 77:1310-1318.
11. Collins P.Y., Patel V., Joestl S.S. Grand challenges in global mental health. Nature 2011, 475:27-30.
12. Cuthbert B.N., Insel T.R. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013, 11:126.
13. Dai X., Zhu B.T. Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions. J. Histochem. Cytochem. 2010, 58:17-28.
14. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-57.
15. Disner S.G., Beevers C.G., Haigh E.A.P., Beck A.T. Neural mechanisms of the cognitive model of depression. Nat. Rev. Neurosci. 2011, 12:467-477.
16. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
17. DSM-5 Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Association, Washington, DC, (Revision American Psychiatric Association, Washington, DC). fifth ed.
18. Duvarci S., Pare D. Amygdala microcircuits controlling learned fear. Neuron 2014, 82:966-980.
19. Eshel N., Roiser J.P. Reward and punishment processing in depression. Biol. Psychiatry 2010, 68:118-124.
20. Feska R.S., Latini A., Rech V.C., Wajner M., Dutra-Filho C.S., de Souza Wyse A.T., Wannmacher C.M.D. Promotion of oxidative stress by l-tryptophan in cerebral cortex of rats. Neurochem. Int. 2006, 49:87-93.
21. Franklin K.B.J., Paxinos G. The Mouse Brain: In Stereotaxic Coordinates 2008, Elsevier, Amsterdam.
22. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., Smith Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 1991, 56:2007-2017.
23. Fullana M.A., Harrison B.J., Soriano-Mas C., Vervilet B., Cardoner N., Avila-Parcet A., Radua J. Neural signatures of human fear conditioning: an updated and extended meta-analysis of fMRI studies. Mol. Psychiatry 2015, 1-9. 10.1038/mp.2015.88.
24. Gal E.M., Sherman A.D. Synthesis and metabolism of l-kynurenine in rat brain. J. Neurochem. 1978, 30:607-613.
25. Gibney S.M., Fagan E.M., Waldron A.-M., O'Byrne J., Connor T.J., Harkin A. Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. Int. J. Neuropsychopharmacol. 2014, 17:917-928.
26. Godlewska B.R., Norbury R., Selvaraj S., Cowen P.J., Harmer C.J. Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol. Med. 2012, 42:2609-2617.
27. Greenberg T., Carlson J.M., Cha J., Hajcak G., Mujica-Parodi L.R. Ventromedial prefrontal cortex reactivity is altered in generalized anxiety disorder during fear generalization. Depress. Anxiety 2013, 30:242-250.
28. Hanke M.L., Powell N.D., Stiner L.M., Bailey M.T., Sheridan J.F. Beta adrenergic blockade decreases the immunomodulatory effects of social disruption stress. Brain Behav. Immun. 2012, 26:1150-1159.
29. Harmer C.J. Emotional processing and antidepressant action. Curr. Topics Behav. Neurosci. 2013, 14:209-222.
30. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
31. Hodes G.E., Pfau M.L., Leboeuf M., Golden S.A., Christoffel D.J., Bregman D., Rebusi N., Heshmati M., Aleysain H., Warren B.L., Lebonte B., Horn S., Lapidus K.A., Stelzhammer V., Wong E.H.F., Bahn S., Krishnan V., Bolanos-Guzman C.A., Murrough J.W., Merad M., Russo S.J. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. PNAS 2014, 111:16136-16141.
32. Inagaki T.K., Muscatell K.A., Irwin M.R., Cole S.W., Eisenberger N.I. Inflammation selectively enhances amygdala activity to socially threatening images. NeuroImage 2012, 59:3222-3226.
33. Insel T., Cuthbert B., Garvey M., Heinssen R., Pine D.S., Quinn K., Sanislow C., Wang P. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 2010, 167:748-751.
34. Julliard W., Fechner J.H., Mezrich J.D. The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both. Front. Immunol. 2014, 5:1-6.
35. Kendler K.S., Hettema J.M., Butera F., Gardner C.O., Prescott C.A. Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety. Arch. Gen. Psychiatry 2003, 60:789-796.
36. Kessler R.C. The effects of stressful life events on depression. Annu. Rev. Psychol. 1997, 48:191-214.
37. Kiank C., Zeden J.-P., Drude S., Domanska G., Fusch G., Otten W., Schuett C. Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans. PLoS One 2010, 5:e11825.
38. Kim J.J., Jung M.W. Neural circuits and mechanisms involved in Pavlovian fear conditioning: a critical review. Neurosci. Biobehav. Rev. 2006, 30:188-202.
39. Kim H., Chen L., Lim G., Sung B., Wang S., McCabe M.F., Rusanescu G., Yang L., Tian Y., Mao J. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Invest. 2012, 122:2940-2954.
40. Krishnan V., Han M.-H., Graham D.L., Berton O., Renthal W., Russo S.J., LaPlant Q., Graham A., Lutter M., Lagace D.C., Ghose S., Reister R., Tannous P., Green T.A., Neve R.L., Chakravarty S., Kumar A., Eisch A.J., Self D.W., Lee F.S., Tamminga C.A., Cooper D.C., Gershenfeld H.K., Nestler E.J. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007, 131:391-404.
41. Laugeray A., Launay J.-M., Callebert J., Surget A., Belzung C., Barone P.R. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav. Brain Res. 2010, 210:84-91.
42. LeDoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 2000, 23:155-184.
43. Lissek S., Kaczkurkin A.N., Rabin S., Geraci M., Pine D.S., Grillon C. Generalized anxiety disorder is associated with overgeneralization of classically conditioned fear. Biol. Psychiatry 2015, 75:909-915.
44. Liu X., Shin N., Koblish H.K., Yang G., Wang Q., Wang K., Leffet L., Hansbury M.J., Thomas B., Rupar M., Waeltz P., Bowman K.J., Polam P., Sparks R.B., Yue E.W., Li Y., Wynn R., Fridman J.S., Burn T.C., Combs A.P., Newton R.C., Scherle P.A. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010, 115:3520-3530.
45. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATS), both of which contribute to the onset of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:702-721.
46. Maren S., Quirk G.J. Neuronal signalling of fear memory. Nat. Rev. Neurosci. 2004, 5:844-852.
47. Maren S., Phan K.L., Liberzon I. The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat. Rev. Neurosci. 2013, 14:417-428.
48. Marques-Vidal P., Bochud M., Bastardot F., Lüscher T., Ferrero F., Gaspoz J.-M., Paccaud F., Urwyler A., von Känel R., Hock C., Waber G., Preisig M., Vollenweider P. Levels and determinants of inflammatory biomarkers in a Swiss population-based sample (CoLaus Study). PLoS One 2011, 6:e21002.
49. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
50. Miura H., Ando Y., Noda Y., Isobe K., Ozaki N. Long-lasting effects of inescapable-predator stress on brain tryptophan metabolism and the behavior of juvenile mice. Stress 2011, 14:262-272.
51. Mojtabai R. Unmet need for treatment of major depression in the United States. Psychiatr. Serv. 2009, 60:297-305.
52. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., Marshall B., Chandler P., Antonia S.J., Burgess R., Slingluff C.L., Mellor A.L. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297.
53. Nissen C., Holz J., Blechert J., Feige B., Riemann D., Voderholzer U., Normann C. Learning as a model for neural plasticity in major depression. Biol. Psychiatry 2010, 68:544-552.
54. O'Connor J.C., André C., Wang Y., Lawson M.A., Szegedi S.S., Lestage J., Castanon N., Kelley K.W., Dantzer R. Interferon-y and tumor necrosis factor-a mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to Bacillus Calmette-Guérin. J. Neurosci. 2009, 29:4200-4209.
55. O'Connor J.C., Lawson M.A., André C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indolemaine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
56. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30:e36.
57. Phelps E.A., LeDoux J.E. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 2005, 48:175-187.
58. Price J.L., Drevets W.C. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010, 35:192-216.
59. Pryce C.R., Azzinnari D., Sigrist H., Gschwind T., Lesch K.-P., Seifritz E. Establishing a learned helplessness effect paradigm in C57BL/6 mice: behavioural evidence for emotional, motivational and cognitive effects of aversive uncontrollability per se. Neuropharmacology 2012, 62:358-372.
60. Pugh C.R., Kumagawa K., Fleshner M., Watkins L.R., Maier S.F., Rudy J.W. Selective effects of peripheral lipopolysaccharide administration on contextual and auditory-cue fear conditioning. Brain Behav. Immun. 1998, 12:212-229.
61. Ren S., Correia M.A. Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase?. Arch. Biochem. Biophys. 2000, 377:195-203.
62. Rescorla R.A. Pavlovian conditioning: it's not what you think it is. Am. Psychol. 1988, 43:151-160.
63. Reus G.Z., Jansen K., Titus S., Carvalho A.F., Gabbay V., Quevedo J. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies. J. Psychiatr. Res. 2015, 68:316-328.
64. Robinson C.M., Shirey K.A., Carlin J.M. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-y and tumor necrosis factor-a. J. Interferon Cytokine Res. 2003, 23:413-421.
65. Rohleder N. Stimulation of systemic low-grade inflammation by psychosocial stress. Psychosom. Med. 2014, 76:181-189.
66. Savignac H.M., Finger B.C., Pizzo R.C., O'Leary O.F., Dinan T.G., Cryan J.F. Increased sensitivity to the effects of chronic social defeat in an innately anxious mouse strain. Neuroscience 2011, 192:524-536.
67. Savitz J., Frank M.B., Victor T.A., Bebak M., Marino J.H., Bellgowan P.S.F., Mckinney B.A., Bodurka J., Teague T.K., Drevets W.C. Inflammation and neurological disease-related genes are differentially expressed in depressed patients with mood disorders and correlate with morphometric and functional abnormalities. Brain Behav. Immun. 2013, 31:161-171.
68. Savitz J., Drevets W.C., Smith C.M., Victor T.A., Wurfel B.E., Bellgowan P.S.F., Bodurka J., Teague T.K., Dantzer R. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 2015, 43:463-471.
69. Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.-Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 2012, 13:465-477.
70. Sheline Y.I., Barch D.M., Donnelly J.M., Ollinger J.M., Snyder A.Z., Mintun M.A. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol. Psychiatry 2001, 50:651-658.
71. Siegert R.J., Abernethy D.A. Depression in multiple sclerosis: a review. J. Neurol. Neurosurg. Psychiatry 2004, 76:469-475.
72. Steiner J., Walter M., Gos T., Guillemin G.J., Bernstein H.-G., Sarnyai Z., Mawrin C., Brisch R., Bielau H., Meyer zu Schwabedissen L., Bogerts B., Myint A.-M. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. J. Neuroinflamm. 2011, 8:94.
73. Sublette M.E., Galfalvy H.C., Fuchs D., Lapidus M., Grunebaum M.F., Oquendo M.A., Mann J.J., Postolache T.T. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav. Immun. 2011, 25:1272-1278.
74. Thomson L.M., Sutherland R.J. Systemic administration of lipopolysaccharide and interleukin-1B have different effects on memory consolidation. Brain Res. Bull. 2005, 67:24-29.
75. Toghi H., Utsugisawa K., Yamagata M., Yoshimura M. Effects of age on messenger RNA expression of glucocorticoid, thyroid hormon, androgen, and estrogen receptors in postmortem human hippocampus. Brain Res. 1995, 700:245-253.
76. Vecsei L., Szalardy L., Fulop F., Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 2013, 12:64-82.
77. Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G., Wachter H. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochem. Biophys. Acta 1989, 1012:140-147.
78. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jönsson B., Olesen J., Allgulander C., Alonso J., Faravelli C., Fratiglioni L., Jennum P., Lieb R., Maercker A., van Os J., Preisig M., Salvador-Carulla L., Simon R., Steinhausen H.-C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011, 21:655-679.
79. Wohleb E.S., Hanke M.L., Corona A.W., Powell N.D., Stiner L.M., Bailey M.T., Nelson R.J., Godbout J.P., Sheridan J.F. B-adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J. Neurosci. 2011, 31:6277-6288.
80. Wohleb E.S., Powell N.D., Godbout J.P., Sheridan J.F. Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. J. Neurosci. 2013, 33:13820-13833.
81. Wolff S.B.E., Gründemann J., Tovote P., Krabbe S., Jacobson G.A., Müller C.E., Herry C., Ehrlich I., Friedrich R.W., Letzkus J.J., Lüthi A. Amygdala interneuron subtypes control fear learning through disinhibition. Nature 2014, 509:453-458.
82. Yeung A.W.S., Terentis A.C., King N.J.C., Thomas S.R. Role of indoleamine 2,3-dioxygenase in health and disease. Clin. Sci. 2015, 129:601-672.
83. Yu T., Guo M., Garza J., Rendon S., Sun X.L., Zhang W., Lu X.Y. Cognitive and neural correlates of depression-like behaviour in socially defeated mice: an animal model of depression with cognitive dysfunction. Int. J. Neuropsychopharmacol. 2011, 14:303-317.
84. Yue E.W., Douty B., Wayland B., Bower M., Liu X., Leffet L., Wang Q., Bowman K.J., Hansbury M.J., Liu C., Wei M., Li Y., Wynn R., Burn T.C., Koblish H.K., Fridman J.S., Metcalf B., Scherle P.A., Combs A.P. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J. Med. Chem. 2009, 52:7364-7367.
85. Zhu H., Bogdanov M.B., Boyle S.H., Matson W., Sharma S., Matson S., Churchill E., Fiehn O., Rush J.A., Krishnan R.R., Pickering E., Delnomdedieu M., Kaddurah-Daouk R., Network P.R. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One 2013, 8:1-12.